| Product Name | GLYPRESSIN SOLUTION FOR INJECTION, 1 MG/8.5 ML |
| Active Ingredient (Strength) | Terlipressin 0.85 mg/8.5 ml eqv Terlipressin acetate(1 mg/8.5 ml) |
| Product Registrant | FERRING PHARMACEUTICALS PRIVATE LIMITED |
| Date of Approval | 10/07/2024 |
| Indications: Treatment of patients with hepatorenal syndrome (HRS) Type 1 who are actively being considered for liver transplant (see sections 4.2 and 4.4 on the risks in special populations). | |
| Product Name | REXULTI FILM-COATED TABLETS 0.5MG, REXULTI FILM-COATED TABLETS 1MG, REXULTI FILM-COATED TABLETS 2MG, REXULTI FILM-COATED TABLETS 3MG |
| Active Ingredient (Strength) | BREXPIPRAZOLE(0.5mg), BREXPIPRAZOLE(1mg), BREXPIPRAZOLE(2mg), BREXPIPRAZOLE(3mg) |
| Product Registrant | LUNDBECK SINGAPORE PTE. LTD. |
| Date of Approval | 24/07/2024 |
| Indications: Treatment of agitation associated with Alzheimer’s dementia (AAD), who are unresponsive to non-pharmacological interventions. | |
| Product Name | PREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML, PREVYMIS FILM COATED TABLET 240MG, PREVYMIS FILM COATED TABLET 480MG |
| Active Ingredient (Strength) | Letermovir(20mg/ml), Letermovir(240.0mg), Letermovir(480.0mg) |
| Product Registrant | MSD PHARMA (SINGAPORE) PTE. LTD. |
| Date of Approval | 01/07/2024 |
| Indications: Prevymis is indicated for prophylaxis of CMV disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-]. | |
| Product Name | HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML |
| Active Ingredient (Strength) | Adalimumab(40 mg/0.8 mL) |
| Product Registrant | NOVARTIS (SINGAPORE) PTE LTD |
| Date of Approval | 18/07/2024 |
| Indications: Pediatric Ulcerative Colitis Hyrimoz is indicated for inducing and maintaining clinical remission in pediatric patients 5 years of age or older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. | |
| Product Name | ULTRAVIST 300 INJECTION 300MG IODINE/ML ULTRAVIST 370 INJECTION 370MG IODINE/ML |
| Active Ingredient (Strength) | Iopromide eqv iodine (300mg/ml), Iopromide eqv iodine (370mg/ml) |
| Product Registrant | BAYER (SOUTH EAST ASIA) PTE LTD |
| Date of Approval | 27/07/2024 |
| Indications: For use in contrast-enhanced mammography to assess and detect known or suspicious lesions of the breast in adult women as an adjunct to mammography (with or without ultrasound). | |
HSA: Health Sciences Authority
Link to the HSA announcement: https://www.hsa.gov.sg/announcements/new-drug-indication-approvals/new-drug-indication-approval—july-2024
Only Authentic Products and Genuine Medical Supplies, at POM Marketplace!
Login or Register now to access our comprehensive range of medical supplies.
Disclaimer: The information provided on this page is intended solely for healthcare professionals for informational purposes only. While we strive for accuracy, POMConnect assumes no liability for errors or omissions. The content here should not be considered a substitute for professional medical advice. POMConnect does not endorse specific treatments or external websites linked from this page. Please note that the information is accurate at the time of publication and does not account for any modifications or updates made to the original research article after its initial publish date. POM Marketplace is accessible to qualified healthcare professionals only. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
